Seemingly bad news can sometimes be really good news. I think a recent study for Eli Lilly's (NYSE: LLY) rival to Novo Nordisk's massively successful Ozempic and Wegovy provides a great case in point.
Results from the Surmount-4 clinical trial were published on the Journal of the American Medical Association's website on Dec. 11, 2023. Researchers found that patients who took Lilly's weight loss drug tirzepatide (marketed as Zepbound for weight loss and Mounjaro for type 2 diabetes) regained roughly half of their weight after they stopped taking the drug for one year.
Investors reacted negatively to the news. Lilly's share price fell around 5% before rebounding somewhat. However, my view is that there's more to the story that many investors are missing. Here's why the recent data actually makes Lilly stock an even better buy.
No Gilead effect here
To make my argument, let me first point to a completely opposite scenario that I think is instructive. A decade ago, Gilead Sciences(NASDAQ: GILD) won U.S. Food and Drug Administration (FDA) approval for Sovaldi. It was the first therapy that effectively cured hepatitis C for many patients.
Over the next few years, Gilead launched even more powerful combination therapies for treating hepatitis C virus (HCV) infection. Harvoni, Epclusa, and Biktarvy -- along with Sovaldi -- all became blockbusters. Gilead raked in money hand over fist.
Everything went great for Gilead Sciences for a while. But then, the company's sales began to decline, as did the price of the biotech stock. What happened?
A person who is cured of hep C doesn't need medications anymore. Gilead began to run out of patients for its HCV drugs.
As I mentioned, this is the opposite scenario than we're seeing for Eli Lilly and Zepbound. Patients have ample motivation to continue taking Lilly's drug. If they don't, they're likely to regain their lost weight.
This means that Lilly isn't going to experience the "Gilead effect." Sales for Zepbound should remain strong as patients continue taking the drug to keep their weight down.
No one should have expected a different outcome, though. Research has also shown that patients who stop taking Novo Nordisk's Ozempic and Wegovy regain weight. In addition, Lilly Chief Scientific and Medical Officer Dan Skovronsky stated earlier this year that "unfortunately, tirzepatide is probably like every other drug we have which requires you to take it to continue to get the benefits." His use of the word "unfortunately" applies to patients and payers -- it's very fortunate for Lilly and its shareholders.
Lilly's abundance of riches
The combination of Mounjaro and Zepbound could generate peak annual sales of more than $50 billion if analysts' projections are on target. Lilly could very well soon have the world's best-selling drug.
But while Mounjaro/Zepbound is the company's crown jewel, Lilly has an abundance of riches in its current product lineup and pipeline. Verzenio is already a blockbuster in treating breast cancer, with sales skyrocketing 68% year over year in the third quarter of 2023. It's in late-stage testing for treating prostate cancer, as well.
Sales for two other cancer therapies -- Retevmo and Tyvyt -- soared at least 50% year over year in Q3. Lilly's type 2 diabetes drug Jardiance continues to perform well, with sales jumping 22% in the recent quarter. The company remains a major player in the autoimmune disease market with Taltz and Olumiant enjoying solid momentum.
The big drugmaker hopes to soon win FDA approval for donanemab in treating early stage Alzheimer's disease. It seeks to add another autoimmune disease drug to its portfolio with lebrikizumab in treating atopic dermatitis.
Lilly could further boost its type 2 diabetes and weight loss franchise with orforglipron, an oral therapy that's in phase 3 clinical studies. And those are just a few of the company's promising pipeline candidates.
That seemingly bad news with the data released recently about tirzepatide truly is good news for Eli Lilly. I expect that the drugmaker and its shareholders will have plenty of more good news on the way over the next few years.
Should you invest $1,000 in Eli Lilly right now?
Before you buy stock in Eli Lilly, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now... and Eli Lilly wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The Stock Advisor service has more than tripled the return of S&P 500 since 2002*.
*Stock Advisor returns as of December 11, 2023
Keith Speights has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Gilead Sciences. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy.
